Intended for licensed healthcare professionals located in Switzerland.
Professional Information - Switzerland
ICLUSIG
home
ICLUSIG
patient profiles
View expert videos
on ICLUSIG
ICLUSIG
resources
Because Tomorrows Matters Today
Blue square
Resources for ICLUSIG

Learn more about the treatment
for CML and Ph+ ALL

ICLUSIG has been with you since 2014. At this 10-year milestone, we celebrate the combined experience and data we’ve built with ICLUSIG that may improve patients’ futures.1,2
Video intro icon

ICLUSIG 10-year anniversary video

Play the video below to learn more about the key milestones of ICLUSIG and celebrate together the progress made over the past decade in the treatment of patients with CML and Ph+ ALL.

Watch a series of short videos
where experts tell the ICLUSIG story
Click here

*ICLUSIG was approved for the European market in 2013 and by Swissmedic in 2014.

Abbreviations: CML, chronic myeloid leukaemia; Ph+ ALL, Philadelphia chromosome-positive acute lymphoblastic leukaemia.

References: 1. Cortes JE, et al. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393─404; 2. Cortes JE, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138:2042─50.

All references are available upon request.

Privacy Policy Cookie Policy Terms of Use Imprint

CH/ICLG/P/24/0017
Date of preparation: August 2024

© 2025, Incyte. All rights reserved.
Marketing authorisation holder: Incyte Biosciences International Sàrl.
ICLUSIG, the ICLUSIG logo and the Incyte logo are registered trademarks of Incyte.

If you would like to request further medical information, please visit:
www.incyteglobalmedicalinformation.com